Resveratrol protects against methotrexate-induced hepatic injury in rats

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 2, 2010, Pages 303-310

  Tunali Akbay, Tugba ^a   Sehirli, Ozer ^a   Ercan, Feriha ^b   Sener, Goksel ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; COLLAGEN; GLUTATHIONE; LACTATE DEHYDROGENASE; MALONALDEHYDE; METHOTREXATE; MYELOPEROXIDASE; RESVERATROL; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER INJURY; LIVER PROTECTION; MALE; NONHUMAN; RAT;

EID: 78650377859     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j30k5q     Document Type: Article

References (42)

1. Jolivet J, Cowan KH, Curt GA. Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med, 1983; 309:1094-1104.
2. Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol, 2009; 21: 216-223.
3. Guzzo C. Folic acid supplementation with methotrexate therapy: What benefit if any? J Am Acad Dermatol, 1994; 31: 689.
4. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol, 2000; 42:531-534.
5. Henning JS, Gruson LM, Strober BE. Reconsidering liver biopsies during methotrexate therapy, J Am Acad Dermatol, 2007; 56: 893-894.
6. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol, 2009; 146:489-503.
7. Ignatowicz E, Baer-Dubowska W. Resveratrol, a natural chemopreventive agent against degenerative diseases. Pol J Pharmacol, 2001; 53: 557-569.
8. Soleas GJ, Yan J, Goldberg DM Absorption of trans-resveratrol in rats. Methods Enzymol, 2001; 335: 130-145.
9. Leonard S, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, Shi X. Biochem Biophys Res Commun, 2003; 309: 1017-1026.
10. Gusman J, Malonne H, Atassi G. A reappraisal of the potential chemopreventive and chemo therapeutic properties of resveratrol. Carcinogenesis, 2001; 22: 1111-1117.
11. Jang M Pezzuto JM.: Cancer chemopreventive activity of resveratrol. Drug Exp Clin Res, 1999; 25: 65-77.
12. Mayo JC, Tan DX, Sainz RM, Natarajan M, Lopez-Burillo S, Reiter RJ. Protection againstoxidative protein damage induced by metalcatalyzed reaction or alkylperoxyl radicals: comparative effects of melatonin and other antioxidants. Biochim Biophys Acta, 2003; 1620: 139-150.
13. Zini R, Morin C, Bertelli A, Bertelli AA, Tillement JP. Drugs Exp Clin Res, 1999; 25: 87-97.
14. Martínez J, Moreno JJ. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol, 2000; 59: 865-870.
15. Losa GA. Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur J Clin Invest, 2003; 33: 818-823.
16. Orallo F, Alvarez E, Camina M, Leiro JM, Gomez E, Fernandez P. The possible implication of trans- Resveratrol in the cardioprotective effects of longterm moderate wine consumption. Mol Pharmacol, 2002; 61: 294-302.
17. Beuge JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol, 1978; 52:302-311.
18. Beutler, E., Glutathione in red blood cell metabolism, in: A manual of biochemical methods. New York: Grune and Stratton, pp 112-114, 1975.
19. Hillegas LM, Griswold DE, Brickson B, Albrightson-Winslow C. Assesment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods, 1990; 24:285-295.
20. Ingram GI, Hills M. Reference method for the one-stage prothrombin-time test on human blood. Thromb Haemost, 1976; 36: 237-238.
21. Lopez De Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin embedded sections. J Histochem Cytochem, 1985; 33:737-743.
22. Neuman MG, Cameron RG, Haber JA, Katz GG, Malkewcz IM, Shear NH. Inducers of cyto-chrome P450 2E1 enhance methotrexate - induced hepatotoxicity. Clin Biochem, 1999; 32:519-536.
23. Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics, 2004;5, 819-834.
24. Babiak RM, Campello AP, Carnieri EG, Olivera MB. Methotrexate: pentose cycle and oxidative stress. Cell Biochem Funct, 1998; 16: 283-293.
25. Chladek J, Martinkova J, Sispera L. An in vitro study on methotraxate hydoxylation in rat and human liver. Physiol Res, 1997; 46:371-379.
26. Galivan J, Nimec Z, Balinska M. Regulation of methotrexate polyglutamate accumulation in vitro: effects of cellular folat content. Biochem Pharmacol, 1983; 32:3344-3347.
27. Kamen BA, Nylen PA, Camitta BM, Bertno JR. Methotrexate accumulation and folate depletion in cell as a possible mechanism of chronic toxicity to the drug. Br J Hematol, 1981; 49:355-360.
28. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexateassociated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol, 2008; 160:622-628.
29. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Arth Rheum, 1986; 29:832-835.
30. Vogel WH, Snyder R, Schulman MP. The inhibition of dehydrogenases by folic acid and several of its analogs. Biochim Biophys Res Comm, 1963; 10:97-101.
31. Caetano NN, Campello AP, Carnieri EGS, Kluppel MLW, Oliveira MBM. Effects of methotrexate (MTX) on NAD(P)+ dehydrogenases of HeLa cells: malic enzymes, 2-oxoluterate and isocitrate dehydrogenases. Cell Biochem Funct, 1997; 15:259-264.
32. Jahovic N, Cevik HA, Sehirli O, Yegen BC, Sener G. Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res, 2003; 34:282-287
33. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J, 2003;17: 1975-85.
34. Cetin A, Kaynar L, Kocyigit I, Hacioglu SK, Saraymen R, Ozturk A, Sari I, Sagdic O. Role of grape seed extract on methotrexate induced oxidative stress in rat liver.Am J Chin Med, 2008;36; 861-872.
35. Upadhyay G, Singh AK, Kumar A, Prakash O, Singh MP. Resveratrol modulates pyrogallolinduced changes in hepatic toxicity markers, xenobiotic metabolizing enzymes and oxidative stress. Eur J Pharmacol, 2008; 596: 146-152.
36. Bujanda L, García-Barcina M, Gutiérrez-de Juan V, Bidaurrazaga J, de Luco MF, Gutiérrez-Stampa M, Larzabal M, Hijona E, Sarasqueta C, Echenique-Elizondo M, Arenas JI. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol, 2006; 6:35.
37. Lin HI, Chu SJ, Wang D, Feng NH. Pharmacological modulation of TNF production in macrophages. J Microbiol Immunol Infect, 2004; 37: 8-15.
38. Sullivan GW, Sarembock IJ, Linden J. The role of inflammation in vascular diseases. J Leukoc Biol, 2000; 67:591-602.
39. Bachlie E. History of tissue factor. Br J Haematol, 2000; 110: 248-255.
40. Lwaleed BA, Francis JL, Chrisholm M. Urinary tissue factor levels in neoplastic disease. Ann Saudi Med, 2000; 20: 197-201.
41. Tutuarima JA, Hische EAH, Trotsenburg L, Helm, HJ. Thromboplastic activity of cerebrospinal fluid in neurological disease. Clin Chem, 1985; 31: 99-100.
42. Yarat A, Tunali T, Pisiriciler R, Akyuz S, Ipbuker A, Emekli N. Salivary thromboplastic activity in diabetics and healthy controls. Clin Oral Invest, 2004; 8: 36-39.